About

On August 3, 2026, Danaher's Board of Directors appointed Julie Sawyer Montgomery President and Chief Executive Officer and a member of the Board of Directors, effective October 1, 2026, succeeding Rainer M. Blair. She currently serves as Executive Vice President of Danaher, with responsibility for the Diagnostics platform.

Since joining Danaher in 2017 at Beckman Coulter Diagnostics, where she led commercial operations and R&D before becoming President in 2020, Ms. Sawyer Montgomery has played a central role in transforming Danaher's Diagnostics platform into a market-leading franchise, helping grow the business from approximately $6.0 billion in revenue in 2017 to approximately $11.0 billion today while roughly tripling operating profit. She led Danaher's recent acquisition of Masimo and its pending acquisition of StatLab, and has worked to optimize the Danaher Business System across the Life Sciences and Diagnostics businesses. She brings nearly 25 years of experience across healthcare, commercial operations and R&D.

She has served as Executive Vice President of Danaher since July 2024, after serving as Vice President - Group Executive of Danaher's Diagnostics subsidiary from January 2023 to June 2024 and President of Danaher's Beckman Coulter Diagnostics subsidiary from January 2020 to December 2022.

Roles

Danaher Corp.
President and Chief Executive Officer; member of the Board of Directors (Executive, Finance and Science & Technology Committees) (effective October 1, 2026) · Current role
2017–present
Danaher Corporation (Diagnostics)
Vice President – Group Executive
January 2023 – June 2024
Beckman Coulter Diagnostics
President · A Danaher subsidiary.
January 2020 – December 2022
Danaher Corporation (Beckman Coulter Diagnostics)
Joined Danaher; roles of increasing responsibility in commercial operations and R&D, then President of Beckman Coulter Diagnostics · Per Danaher's official leadership bio.
2017 – 2022
Hospira Infusion Systems
Leadership roles · Held prior to joining Danaher, per the official bio.
Boston Scientific
Leadership roles · Held prior to joining Danaher, per the official bio.
Boston Consulting Group
Leadership roles · Held prior to joining Danaher, per the official bio.

Fixed Compensation

FY 2025
Salary
$848,000
ComponentAnnual base salary
Bonus
$0
All other compensation
$139,623
Total compensation
$11,295,279

Performance Compensation

Data from FY 2025

Cash incentive

Annual cash incentive
$1,587,880
FormCash
Target Opportunity
Evaluation periodFY2025

Stock awards

Stock awards
$4,425,309
Formas disclosed
Vestingas disclosed

Also at Danaher Corp.

Related

See how VectorShift works for your firm

Request Demo